NRX Pharmaceuticals (NRXP) Operating Leases (2025 - 2026)

NRX Pharmaceuticals' (NRXP) quarterly Operating Leases came in at $934000.0 in Q1 2026, up 369.35% on a QoQ basis from $199000.0 in Q4 2025.

NRX Pharmaceuticals (NRXP) Operating Leases (2025 - 2026) Analysis & Trends

NRX Pharmaceuticals (NRXP) has 2 years of Operating Leases data on file, last reported at $934000.0 in Q1 2026.

On a quarterly basis, Operating Leases changed N/A year-over-year to $934000.0 in Q1 2026; TTM through Mar 2026 was $934000.0, a N/A change from a year earlier, with the FY2025 full-year figure at $199000.0, changed N/A from the prior year.
Operating Leases for Q1 2026 stood at $934000.0, up from $199000.0 in the prior quarter.
Over the last five years, Operating Leases for NRXP reached as high as $934000.0 in Q1 2026 and fell as low as $143000.0 in Q3 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Oculis Holding AG	68,785.72 Bn	68,785.72 Bn	-
2	Nanobiotix	1,895.57 Bn	1,895.51 Bn	-
3	BeOne Medicines	471.35 Bn	466.56 Bn	1.35 Bn
4	NuCana	279.75 Bn	279.75 Bn	-
5	Vertex Pharmaceuticals	120.24 Bn	113.00 Bn	2.59 Bn
6	Regeneron Pharmaceuticals	67.80 Bn	59.04 Bn	3.31 Bn
7	Belite Bio	62.51 Bn	62.51 Bn	-
8	Argenx Se	57.38 Bn	57.38 Bn	1.41 Bn
9	Revolution Medicines	37.78 Bn	37.78 Bn	-
10	NRX Pharmaceuticals	137.57 Mn	130.87 Mn	437,000.00

Download Data